Double-Blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients with Celiac Disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Small intestinal bacterial overgrowth (SIBO) is one cause of a poor response to a gluten-free diet (GFD) and persistent symptoms in celiac disease. Rifaximin has been reported to improve symptoms in non-controlled trials.
To determine the effect of rifaximin on gastrointestinal symptoms and lactulose-hydrogen breath tests in patients with poorly responsive celiac disease.
A single-center, double-blind, randomized, controlled trial of patients with biopsy-proven celiac disease and persistent gastrointestinal symptoms despite a GFD was conducted. Patients were randomized to placebo (n = 25) or rifaximin (n = 25) 1,200 mg daily for 10 days. They completed the Gastrointestinal Symptom Rating Scale (GSRS) and underwent lactulose-hydrogen breath tests at weeks 0, 2, and 12. An abnormal breath test was defined as: (1) a rise in hydrogen of ≥20 parts per million (ppm) within 100 min, or (2) two peaks ≥20 ppm over baseline.
GSRS scores were unaffected by treatment with rifaximin, regardless of baseline breath tests. In a multivariable regression model, the duration of patients’ gastrointestinal symptoms significantly predicted their overall GSRS scores (estimate 0.029, p < 0.006). According to criteria 1 and 2, respectively, SIBO was present in 55 and 8% of patients at baseline, intermittently present in 28 and 20% given placebo, and 28 and 12% given rifaximin. There was no difference in the prevalence of SIBO between placebo and treatment groups at weeks 2 and 12.
Rifaximin does not improve patients’ reporting of gastrointestinal symptoms and hydrogen breath tests do not reliably identify who will respond to antibiotic therapy.
- Green, P, Cellier, C (2007) Celiac disease. N Engl J Med 357: pp. 1731-1743 CrossRef
- O’Mahony, S, Howdle, P, Losowsky, M (1996) Review article: management of patients with non-responsive coeliac disease. Aliment Pharmacol Ther 10: pp. 671-680 CrossRef
- Abdallah, H, Leffler, D, Dennis, M, Kelly, C (2007) Refractory celiac disease. Curr Gastroenterol Rep 9: pp. 401-405 CrossRef
- Fine, KD, Meyer, RL, Lee, EL (1997) The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet. Gastroenterology 112: pp. 1830-1838 CrossRef
- Rubio-Tapia, A, Barton, SH, Rosenblatt, JE, Murray, JA (2009) Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. J Clin Gastroenterol 43: pp. 157-161 CrossRef
- Tursi, A, Brandimarte, G, Giorgetti, G (2003) High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol 98: pp. 839-843 CrossRef
- Rana, SV, Sinha, SK, Lal, S, Sikander, A, Singh, K (2007) Small intestinal bacterial overgrowth in North Indian patients with celiac disease. Trop Gastroenterol 28: pp. 159-161
- Abdulkarim, AS, Burgart, LJ, See, J, Murray, JA (2002) Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 97: pp. 2016-2021 CrossRef
- Prizont, R, Hersh, T, Floch, MH (1970) Jejunal bacterial flora in chronic small bowel disease. I. Celiac disease. II. Regional enteritis. Am J Clin Nutr 23: pp. 1602-1607
- Quigley, E, Quera, R (2006) Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 130: pp. S78-S90 CrossRef
- Rana, S, Bhardwaj, S (2008) Small intestinal bacterial overgrowth. Scand J Gastroenterol 43: pp. 1030-1037 CrossRef
- Corazza, G, Menozzi, M, Strocchi, A (1990) The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 98: pp. 302-309
- Ghoshal U, Ghoshal U, Misra A, Choudhuri G. Partially responsive celiac disease resulting from small intestinal bacterial overgrowth and lactose intolerance. BMC Gastroenterol. 2004;10.
- Roufail, WM, Ruffin, JM (1966) Effect of antibiotic therapy on gluten-sensitive enteropathy. Am J Dig Dis 11: pp. 587-593 CrossRef
- Pelosini I, Scarpignato C. Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. Chemotherapy. 2005;122–130.
- Lauritano, E, Gabrielli, M, Lupascu, A (2005) Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 22: pp. 31-35 CrossRef
- Scarpellini E, Gabrielli M, Lauritano E, et al. High-dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2007;25:781–786.
- Svedlund J, Sjodin I, Dotevall G. GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33:129–134.
- Sharara, AI, Aoun, E, Abdul-Baki, H, Mounzer, R, Sidani, S, Elhajj, I (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101: pp. 326-333 CrossRef
- Pimentel, M, Chow, EJ, Lin, HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98: pp. 412-419
- Corazza, GR, Strocchi, A, Gasbarrini, G (1987) Fasting breath hydrogen in celiac disease. Gastroenterology 93: pp. 53-58
- Pimentel, M, Chow, EJ, Lin, HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95: pp. 3503-3506 CrossRef
- Walters, B, Vanner, SJ (2005) Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 100: pp. 1566-1570 CrossRef
- Pimentel, M (2009) Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 18: pp. 349-358 CrossRef
- Mustalahti, K, Lohiniemi, S, Collin, P, Vuolteenaho, N, Laippala, P, Mäki, M (2002) Gluten-free diet and quality of life in patients with screen-detected celiac disease. Eff Clin Pract 5: pp. 105-113
- Lohiniemi, S, Mäki, M, Kaukinen, K, Laippala, P, Collin, P (2000) Gastrointestinal symptoms rating scale in coeliac disease patients on wheat starch-based gluten-free diets. Scand J Gastroenterol 35: pp. 947-949 CrossRef
- Hallert, C, Granno, C, Grant, C (1998) Quality of life of adult coeliac patients treated for 10 years. Scand J Gastroenterol 33: pp. 933-938 CrossRef
- Hopman, EG, Koopman, HM, Wit, JM, Mearin, ML (2009) Dietary compliance and health-related quality of life in patients with coeliac disease. Eur J Gastroenterol Hepatol 21: pp. 1056-1061 CrossRef
- Nachman, F, Vazquez, H, Gonzalez, A (2011) Gastroesophageal reflux symptoms in patients with celiac disease and the effects of a gluten-free diet. Clin Gastroenterol Hepatol 9: pp. 214-219 CrossRef
- Midhagen, G, Hallert, C (2003) High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study. Am J Gastroenterol 98: pp. 2023-2026 CrossRef
- Pimentel, M, Lembo, A, Chey, WD (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364: pp. 22-32 CrossRef
- Leffler, D, Dennis, M, Hyett, B, Kelly, E, Schuppan, D, Kelly, C (2007) Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 5: pp. 445-450 CrossRef
- Dorn, SD, Hernandez, L, Minaya, MT (2010) Psychosocial factors are more important than disease activity in determining gastrointestinal symptoms and health status in adults at a celiac disease referral center. Dig Dis Sci 55: pp. 3154-3163 CrossRef
- Gasbarrini, A, Lauritano, E, Gabrielli, M (2007) Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 25: pp. 237-240 CrossRef
- Khoshini, R, Dai, SC, Lezcano, S, Pimentel, M (2008) A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 53: pp. 1443-1454 CrossRef
- Double-Blind Randomized Controlled Trial of Rifaximin for Persistent Symptoms in Patients with Celiac Disease
Digestive Diseases and Sciences
Volume 56, Issue 10 , pp 2939-2946
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Celiac disease
- Small intestine
- Clinical pharmacology
- Symptom score or index
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine, Columbia University College of Physicians and Surgeons, 180 Fort Washington Avenue, New York, NY, 10032, USA
- 2. Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA
- 3. Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA